Dr. Aseem Malhotra on pharma: what the evidence says · JRE #1979
SUBJECT: PHARMA
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
between 2003 and 2016, most of the top 10 drug companies paid fines totaling about $33 billion for illegal marketing of drugs, hiding data on harms, and manipulation of results
What the evidence says 01 / RECORD
A peer-reviewed 2020 JAMA research letter (Arnold, Stewart, and Beck) analyzed financial penalties levied on 26 large pharmaceutical firms (Global 500/Fortune 1000) for illegal activities between January 2003 and December 2016, using US Department of Justice, SEC, EPA, and state attorneys general settlement data. The study found the combined dollar value of financial penalties totaled exactly $33 billion for 2003 to 2016 (in inflation-adjusted 2016 dollars), with 22 of 26 firms (85%) incurring at least one penalty. Eleven firms with penalties exceeding $1 billion accounted for $28.8 billion (88%) of the total. Per the study's published per-firm table, the ten highest-penalized firms (GlaxoSmithKline, Pfizer, Johnson & Johnson, Abbott, Merck, Eli Lilly, Schering-Plough, Wyeth, Bristol Myers Squibb, and Novartis) together accounted for roughly $27.7 billion, about 84% of the $33 billion total. The most common violation categories were pricing violations, off-label marketing, and kickbacks, with misleading marketing and disclosure failures (which cover deceptive promotion and withheld safety information) also well represented, closely matching the claim's description of illegal marketing, hidden harm data, and manipulated results. Malhotra's figure and time frame align precisely with this published academic tally, making the claim well-supported by primary data, though "hiding data on harms" and "manipulation of results" are broader characterizations of some settlement categories (disclosure failures, misleading marketing) rather than a distinct line item in the study.